dexmethylphenidate has been researched along with desvenlafaxine in 2 studies
| Studies (dexmethylphenidate) | Trials (dexmethylphenidate) | Recent Studies (post-2010) (dexmethylphenidate) | Studies (desvenlafaxine) | Trials (desvenlafaxine) | Recent Studies (post-2010) (desvenlafaxine) |
|---|---|---|---|---|---|
| 10 | 0 | 4 | 12 | 0 | 9 |
| Protein | Taxonomy | dexmethylphenidate (IC50) | desvenlafaxine (IC50) |
|---|---|---|---|
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 1.019 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.035 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Subbaiah, MAM | 1 |
2 review(s) available for dexmethylphenidate and desvenlafaxine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Triple Reuptake Inhibitors as Potential Therapeutics for Depression and Other Disorders: Design Paradigm and Developmental Challenges.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Drug Design; Humans; Selective Serotonin Reuptake Inhibitors | 2018 |